Disease · MONDO_0005023

ductal breast carcinoma in situ

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ductal breast carcinoma in situ. Diseases, record MONDO_0005023. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005023

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ductal breast carcinoma in situ; Open Targets
Open Targets ID: MONDO_0005023; Open Targets
Other names: DCIS, breast ductal carcinoma in situ, carcinoma in situ of mammary duct, ductal carcinoma in situ, ductal carcinoma in situ (DCIS), ductal carcinoma in situ of breast, ductal carcinoma in situ of the breast, intraductal breast carcinoma, intraductal carcinoma, intraductal carcinoma of breast, intraductal carcinoma of the breast, mammary duct carcinoma in situ, mammary duct in situ carcinoma, non-infiltrating ductal adenocarcinoma of breast, non-infiltrating ductal adenocarcinoma of the breast, non-infiltrating ductal breast adenocarcinoma, non-infiltrating ductal breast carcinoma, non-infiltrating ductal carcinoma of breast, non-infiltrating ductal carcinoma of the breast, non-infiltrating intraductal adenocarcinoma, non-infiltrating intraductal adenocarcinoma of breast, non-infiltrating intraductal adenocarcinoma of the breast, non-infiltrating intraductal breast adenocarcinoma, non-infiltrating intraductal carcinoma, non-invasive ductal adenocarcinoma of breast, non-invasive ductal adenocarcinoma of the breast, non-invasive ductal breast adenocarcinoma, non-invasive ductal breast carcinoma, non-invasive ductal carcinoma of breast, non-invasive ductal carcinoma of the breast, non-invasive intraductal adenocarcinoma of breast, non-invasive intraductal adenocarcinoma of the breast, non-invasive intraductal breast adenocarcinoma, stage 0 mammary duct carcinoma; Open Targets
Disease Ontology: DOID:0060074; Disease Ontology
MeSH: D002285; MeSH
NCI Thesaurus: C2924; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 7 of its 40 drugs, from ClinicalTrials.gov; Open Targets

Drugs40

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TAMOXIFEN	CHEMBL83	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
ANASTROZOLE	CHEMBL1399	Small molecule	Phase 3	ClinicalTrials.gov	7	7	6	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 40

See all 40 drugs

Targets105

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ESR1	Estrogen receptor	7	Estrogen receptor alpha antagonist; Estrogen receptor alpha degrader; Estrogen receptor alpha modulator; Estrogen receptor degrader; Estrogen receptor modulator	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	4	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 3	https://conductscience.org/library/genes/2064	Drugs and targets
CYP19A1	Aromatase	3	Cytochrome P450 19A1 inhibitor	Phase 3	https://conductscience.org/library/genes/1588	Drugs and targets
EGFR	Epidermal growth factor receptor	3	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
ESR2	Estrogen receptor	3	Estrogen receptor modulator	Phase 2	https://conductscience.org/library/genes/2100	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	3	HMG-CoA reductase inhibitor	Phase 2	https://conductscience.org/library/genes/3156	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	2	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/2820	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4535	Drugs and targets

1 to 10 of 105

See all 105 targets

Trials41

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01275677	Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer	Phase 3	3,270	2020-09-23	HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7	CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00072462	Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ	Phase 3	2,980	2024-09-19	Breast Cancer	ANASTROZOLE, TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT00769379	Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy	Phase 3	2,014	2022-02-23	Breast Ductal Carcinoma In Situ	TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00764322	Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen	Phase 2	501	2017-07-02	Breast Cancer, Menopausal Symptoms	TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT01439711	Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ	Phase 2	108	2018-03-27	Breast Cancer	LETROZOLE	Its record names the disease	ClinicalTrials.gov
NCT02993159	Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast	Phase 2	100	2024-12-18	Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive	AFIMOXIFENE, TAMOXIFEN CITRATE	Its record names the disease	ClinicalTrials.gov
NCT00290745	Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ	Phase 1/2	79	2020-12-04	Breast Cancer	LETROZOLE, TAMOXIFEN CITRATE	Its record names the disease	ClinicalTrials.gov
NCT00496808	Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast	Not applicable	69	2012-05-18	Ductal Carcinoma In Situ	TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00290654	Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ	Phase 2	45	2015-05-15	Breast Cancer	TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT02636582	Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer	Phase 2	43	2023-05-16	Breast Ductal Carcinoma In Situ	NELIPEPIMUT-S, SARGRAMOSTIM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 41

See all 41 trials

Comparisons in its trials26

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause	48 of 1,622	61 of 1,628	3,250	NCT01275677	Trial comparisons
Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events	31 of 1,615	96 of 1,625	3,240	NCT01275677	Trial comparisons
Anastrozole vs Tamoxifen: Number of Breast Cancer Deaths	3 of 1,449	3 of 1,489	2,938	NCT00072462	Trial comparisons
Anastrozole vs Tamoxifen: Number of Participants With ER- Breast Cancer Recurrence	24 of 1,449	15 of 1,489	2,938	NCT00072462	Trial comparisons
Anastrozole vs Tamoxifen: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours	103 of 1,449	120 of 1,489	2,938	NCT00072462	Trial comparisons
Anastrozole vs Tamoxifen: Number of Participants With ER+ Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours	58 of 1,449	82 of 1,489	2,938	NCT00072462	Trial comparisons
Anastrozole vs Tamoxifen: Number of Non-breast Cancer Deaths	59 of 1,449	65 of 1,489	2,938	NCT00072462	Trial comparisons
Anastrozole vs Tamoxifen: deaths from any cause	62 of 1,449	69 of 1,489	2,938	NCT00072462	Trial comparisons
Anastrozole vs Tamoxifen: serious adverse events	333 of 1,449	371 of 1,489	2,938	NCT00072462	Trial comparisons
Standard WBI vs WBI, Trastuzumab: deaths from any cause	11 of 1,005	10 of 993	1,998	NCT00769379	Trial comparisons

1 to 10 of 26

See all 26 comparisons in its trials

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25605856	RESULT	1	PubMed
21885816	RESULT	1	PubMed
19728082	RESULT	1	PubMed
42649946	DERIVED	1	PubMed
41165048	DERIVED	1	PubMed
39980051	DERIVED	1	PubMed
39821301	DERIVED	1	PubMed
38335467	DERIVED	1	PubMed
37870954	DERIVED	1	PubMed
37710198	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005023

GET https://conductscience.org/api/diseases/v1/MONDO_0005023/drugs?page=2

API reference For AI assistants